Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.

Autor:	Rudra S; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Shaul E; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Conrad M; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Patel T; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Moore A; Division of Clinical Pharmacy, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Dawany N; Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Canavan MC; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Sullivan KE; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Division of Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Behrens E; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Kelsen JR; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: kelsen@chop.edu.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2022 Jun; Vol. 20 (6), pp. 1408-1410.e2. Date of Electronic Publication: 2021 Jul 27.
DOI:	10.1016/j.cgh.2021.07.040
Abstrakt:	Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD 1 ; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes. (Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu